Axsome Therapeutics (AXSM) Amortizatization of Intangibles (2015 - 2026)
Axsome Therapeutics (AXSM) reported Amortizatization of Intangibles of $679000.0 for Q1 2026, up 1.8% on a YoY basis from $667000.0 in Q1 2025, and down 34.96% sequentially from $1.0 million in Q4 2025.
Axsome Therapeutics (AXSM) Amortizatization of Intangibles (2015 - 2026) Analysis & Trends
Axsome Therapeutics (AXSM) has 11 years of Amortizatization of Intangibles data on file, last reported at $679000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles rose 1.8% year-over-year to $679000.0; the trailing twelve-month figure through Mar 2026 stood at $2.9 million (down 7.91% YoY), and the FY2025 full-year result was $2.2 million, down 17.2% from the prior year.
- Amortizatization of Intangibles fell to $679000.0 in Q1 2026, from $1.0 million in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $1.9 million in Q4 2024 to a low of $110000.0 in Q1 2024.
- A 5-year average of $549294.1 and a median of $454000.0 in 2023 frame the typical range for Amortizatization of Intangibles.
- Across the five-year window, Amortizatization of Intangibles tumbled 81.16% in 2024 and jumped 506.36% in 2025, its largest moves.
- Tracing AXSM's Amortizatization of Intangibles over 5 years: stood at $346000.0 in 2022, then soared by 31.21% to $454000.0 in 2023, then soared by 327.97% to $1.9 million in 2024, then tumbled by 46.27% to $1.0 million in 2025, then tumbled by 34.96% to $679000.0 in 2026.
- Business Quant data shows AXSM's Amortizatization of Intangibles at $679000.0 in Q1 2026, $1.0 million in Q4 2025, and $684000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | Axsome Therapeutics | 12.28 Bn | 11.98 Bn | 176.48 Mn | 679,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 679,000.00 |
| Mar 31, 2026 | 679,000.00 |
| Dec 31, 2025 | 1.04 Mn |
| Dec 31, 2025 | 1.04 Mn |
| Sep 30, 2025 | 684,000.00 |
| Sep 30, 2025 | 684,000.00 |
| Jun 30, 2025 | 537,000.00 |
| Jun 30, 2025 | 537,000.00 |
| Mar 31, 2025 | 667,000.00 |
| Mar 31, 2025 | 667,000.00 |
| Dec 31, 2024 | 1.94 Mn |
| Dec 31, 2024 | 1.94 Mn |
| Sep 30, 2024 | 324,000.00 |
| Sep 30, 2024 | 324,000.00 |
| Jun 30, 2024 | 263,000.00 |
| Jun 30, 2024 | 263,000.00 |
| Mar 31, 2024 | 110,000.00 |
| Mar 31, 2024 | 110,000.00 |
| Dec 31, 2023 | 454,000.00 |
| Dec 31, 2023 | 454,000.00 |